Catherine's questions to Ocular Therapeutix Inc (OCUL) leadership • Q3 2024
Question
Catherine, on behalf of Jonathan Wolleben, asked if Ocular was reiterating its 2024 guidance for DEXTENZA and requested commentary on how the 2025 CMS rule will affect DEXTENZA's pricing.
Answer
Chief Commercial Officer Steve Meyers confirmed that DEXTENZA remains on track to meet its previously issued guidance. He also expressed that the company is 'very pleased' with the CMS rule, as it reconfirms separate payment for DEXTENZA in the hospital outpatient department (HOPD) setting for 2025.